Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.

Abstract:

BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upgrading or upstaging. The African American (AA) population is under-represented in studies evaluating AS outcomes and this is particularly important because of the unique epidemiology of PCa in AA men. METHODS:A literature review through the Medline database published from 1990 until August 2015 was performed to identify studies reporting outcomes of the AA population with low-risk PCa that underwent either AS or treatment. An additional search for studies on genetic mechanisms involved in development of PCa in AA men was also performed. RESULTS:Eleven studies on pathologic results of AA men who would qualify for AS were identified and in eight of these studies AA race was found to be associated with adverse pathological outcomes such as positive surgical margins, upgrading or upstaging. The other three studies reported no significance in these parameters with respect to race. Five more studies reported outcomes of AS in AA men with different study end points. AA men were mainly found to have a higher rate of disease reclassification subsequent to active treatment. The studies on genetic mechanisms also identified different genetic alterations in the AA population. CONCLUSIONS:AA men with clinically defined low-risk PCa may have either a higher grade or volume of cancer that was not detected on routine evaluation. Therefore, AS among such patients should be approached with caution. We recommend discussing such risks with AA patients with an acknowledgement that existing favorable outcomes noted in largely Caucasian populations may not be applicable to AA patients. We propose a modified evaluation plan for AA patients that includes an early confirmatory biopsy preceded by an magnetic resonance imaging to optimally detect occult cancer foci.

authors

Gökce MI,Sundi D,Schaeffer E,Pettaway C

doi

10.1038/pcan.2016.56

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

127-136

issue

2

eissn

1365-7852

issn

1476-5608

pii

pcan201656

journal_volume

20

pub_type

杂志文章,评审
  • Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial.

    abstract:BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-018-0064-7

    authors: Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

    更新日期:2018-11-01 00:00:00

  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

    abstract:BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0202-x

    authors: Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

    更新日期:2020-09-01 00:00:00

  • Distribution of vascular endothelial growth factor (VEGF) in prostate disease.

    abstract::Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimen...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500575

    authors: Walsh K,Sriprasad S,Hopster D,Codd J,Mulvin D

    更新日期:2002-01-01 00:00:00

  • Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

    abstract:BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2015.48

    authors: Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

    更新日期:2016-03-01 00:00:00

  • Diabetes and prostate cancer risk in the REDUCE trial.

    abstract::Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2011.28

    authors: Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

    更新日期:2011-12-01 00:00:00

  • Effects of soy phytoestrogens on the prostate.

    abstract::Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500953

    authors: Goetzl MA,Van Veldhuizen PJ,Thrasher JB

    更新日期:2007-01-01 00:00:00

  • Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

    abstract::The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4501001

    authors: Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

    更新日期:2008-01-01 00:00:00

  • Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.

    abstract:BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-00280-6

    authors: McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

    更新日期:2020-09-03 00:00:00

  • Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

    abstract::Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500839

    authors: Gould DC,Kirby RS

    更新日期:2006-01-01 00:00:00

  • Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

    abstract::The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2011.14

    authors: Sasaki T,Onishi T,Hoshina A

    更新日期:2011-09-01 00:00:00

  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0224-4

    authors: Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期:2020-12-01 00:00:00

  • Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients.

    abstract:INTRODUCTION:Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). MATERIALS AND METHODS:A total of 102 lymph node positive patients from the RPX series at Ulm University ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500751

    authors: Kuefer R,Volkmer BG,Loeffler M,Shen RL,Kempf L,Merseburger AS,Gschwend JE,Hautmann RE,Sandler HM,Rubin MA

    更新日期:2004-01-01 00:00:00

  • Watchful waiting for prostate cancer: a review article.

    abstract::As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literatu...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500857

    authors: Chodak GW,Warren KS

    更新日期:2006-01-01 00:00:00

  • The management of locally advanced prostate cancer.

    abstract::The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prost...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500620

    authors: Valicenti RK

    更新日期:2002-01-01 00:00:00

  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

    abstract:BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-019-0197-3

    authors: Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

    更新日期:2020-09-01 00:00:00

  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract:BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.3

    authors: Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期:2015-06-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract::Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.61

    authors: Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期:2010-06-01 00:00:00

  • Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

    abstract::Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2010.26

    authors: Choi HY,Lim JE,Hong JH

    更新日期:2010-12-01 00:00:00

  • Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.

    abstract:INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-00315-y

    authors: Shah TT,Reddy D,Peters M,Ball D,Kim NH,Gomez EG,Miah S,Evans DE,Guillaumier S,van Rossum PSN,Van Son MJ,Hosking-Jervis F,Dudderidge T,Hindley R,Emara A,McCracken S,Greene D,Nigam R,McCartan N,Valerio M,Minhas S,

    更新日期:2021-01-28 00:00:00

  • The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng ml(-1.).

    abstract:BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2014.4

    authors: Nafie S,Mellon JK,Dormer JP,Khan MA

    更新日期:2014-06-01 00:00:00

  • A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk.

    abstract:BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2012.41

    authors: Tao L,Chen J,Zhou H,Qin C,Li P,Cao Q,Li J,Ju X,Zhu C,Wang M,Zhang Z,Shao P,Yin C

    更新日期:2013-03-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract::A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500847

    authors: Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期:2006-01-01 00:00:00

  • Primary care physician practices in the diagnosis, treatment and management of men with chronic prostatitis/chronic pelvic pain syndrome.

    abstract::To describe practice patterns of primary care physicians (PCPs) for the diagnosis, treatment and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we surveyed 556 PCPs in Boston, Chicago, and Los Angeles (RR=52%). Only 62% reported ever seeing a patient like the one described in the vignette. I...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.9

    authors: Calhoun EA,Clemens JQ,Litwin MS,Walker-Corkery E,Markossian T,Kusek JW,McNaughton-Collins M

    更新日期:2009-01-01 00:00:00

  • A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

    abstract:BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章

    doi:10.1038/pcan.2015.55

    authors: van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

    更新日期:2016-03-01 00:00:00

  • Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.

    abstract:BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1038/pcan.2014.13

    authors: Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

    更新日期:2014-09-01 00:00:00

  • Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.

    abstract::To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively. Median visual analogue...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.pcan.4500778

    authors: Montgomery BS,Borwell JP,Higgins DM

    更新日期:2005-01-01 00:00:00

  • Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France.

    abstract::The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500517

    authors: Vallancien G,Pariente P

    更新日期:2001-01-01 00:00:00

  • Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy.

    abstract::It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2010.16

    authors: Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU

    更新日期:2011-03-01 00:00:00

  • MRI in active surveillance: a critical review.

    abstract:INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/s41391-018-0077-2

    authors: Stavrinides V,Giganti F,Emberton M,Moore CM

    更新日期:2019-03-01 00:00:00

  • TGFBR1*6A is not associated with prostate cancer in men of European ancestry.

    abstract::The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500765

    authors: Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

    更新日期:2005-01-01 00:00:00